Prestige Consumer Healthcare (PBH) to Post Quarterly Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is expected to be announcing its Q1 2027 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $0.8810 per share and revenue of $250.3350 million for the quarter. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Investors can find conference call details on the company’s upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). The business had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm’s revenue for the quarter was down 5.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.32 earnings per share. On average, analysts expect Prestige Consumer Healthcare to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Trading Down 1.0%

PBH opened at $51.38 on Tuesday. The business has a 50 day simple moving average of $48.37 and a two-hundred day simple moving average of $56.32. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 13.11, a PEG ratio of 1.61 and a beta of 0.35. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare has a one year low of $42.62 and a one year high of $75.31.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PBH shares. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $70.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp raised its holdings in Prestige Consumer Healthcare by 1.4% in the fourth quarter. State Street Corp now owns 1,992,497 shares of the company’s stock worth $122,917,000 after purchasing an additional 27,721 shares in the last quarter. Morgan Stanley lifted its position in Prestige Consumer Healthcare by 6.3% during the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock valued at $74,209,000 after buying an additional 71,078 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 5.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock valued at $45,568,000 after buying an additional 35,126 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Prestige Consumer Healthcare by 19.1% during the 2nd quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after buying an additional 115,459 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in shares of Prestige Consumer Healthcare by 15.7% in the 3rd quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock worth $39,807,000 after buying an additional 86,373 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).